Monitoring the impact of regulatory measures on medicine pricing in Thailand: an observation over a 16-year span.

Abstract

Following a 2007 report by the Thai Food and Drug Administration highlighting disparities in drug pricing across different sectors, there has been a concerted effort to establish and enforce a cohesive medicine pricing policy in Thailand. This study aims to explore the government interventions on medicine pricing in Thailand. Employing a mixed-methods approach, this research included a literature review and a cross-sectional survey of medicine prices using the World Health Organization/Health Action International (WHO/HAI) methodology. Data were collected from both public and private sectors across six provinces in Thailand during April-May 2023. Additionally, international price comparisons were conducted with countries including Australia, Canada, Denmark, Malaysia, and New Zealand. The research identified a significant reduction in the median price ratios (MPRs) of medicines, closer alignment of prices with international benchmarks, and decreased variability in pricing between regions and sectors. These changes illustrated the positive effects of Thailand's pricing policies implemented over the past 16 years. The strategic interventions implemented by the Thai government have markedly enhanced the regulation and affordability of medicine prices. However, to sustain these achievements and ensure the viability of the local pharmaceutical industry, ongoing efforts and policy adaptations are essential. This study emphasises the critical need for continuous evaluation of these policies to respond effectively to evolving healthcare and economic conditions.